Page 121 - 《中国药房》2024年9期
P. 121

·循证药学·


          沙利度胺联合CAG方案治疗老年急性髓系白血病患者有效性与
          安全性的Meta分析
                                       Δ


                                                               #
          李晓靖 ,胡 琦,陆嘉惠,刘 敏,邓剑青,江雯雯,鲍计章(上海中医药大学附属市中医医院血液病科,上海
                *
          200040)

          中图分类号  R979.1      文献标志码  A      文章编号  1001-0408(2024)09-1139-06
          DOI  10.6039/j.issn.1001-0408.2024.09.20

          摘  要  目的  系统评价沙利度胺联合阿克拉霉素、粒细胞集落刺激因子与阿糖胞苷(CAG)方案治疗老年急性髓系白血病
         (AML)患者的疗效与安全性。方法  检索中国知网、万方数据、维普网、Sino Med、PubMed、Embase、 the Cochrane Library、Web of
          Science,检索时限为数据库建库至 2023 年 8 月 27 日。收集沙利度胺联合 CAG 方案(试验组)对比 CAG 方案(对照组)治疗老年
          AML患者的临床随机对照试验,对纳入的研究采用RevMan 5.3软件进行Meta分析。结果  最终纳入7项临床随机对照试验,共计
          601 例患者,其中试验组 307 例、对照组 294 例。Meta 分析结果显示,试验组在提升总有效率[Z=4.75,P<0.000 01,OR=2.80,
          95%CI(1.83,4.28)]、完全缓解率[Z=2.82,P=0.005,OR=1.61,95%CI(1.16,2.25)],改善血小板计数[Z=2.70,P=0.007,MD=
          64.02,95%CI(17.53,110.51)]、血管内皮生长因子水平[Z=13.63,P<0.000 01,MD=-65.17,95%CI(-74.54,-55.80)]、血管内皮生长
          因子受体水平[Z=12.03,P<0.000 01,MD=-499.01,95%CI(-580.31,-417.71)]、碱性成纤维细胞生长因子水平[Z=4.17,P<
          0.000 1,MD=-0.23,95%CI(-0.35,-0.12)]等方面均显著优于对照组,不良反应发生率[Z=0.99,P=0.32,OR=0.52,95%CI
         (0.14,1.89)]以及恶心呕吐[Z=1.06,P=0.29,OR=0.66,95%CI(0.30,1.43)]、便秘或腹泻[Z=0.92,P=0.36,OR=0.65,95%CI
         (0.26,1.63)]、嗜睡[Z=1.38,P=0.17,OR=0.57,95%CI(0.26,1.27)]、骨髓抑制[Z=0.88,P=0.38,OR=0.68,95%CI(0.28,1.62)]的
          发生率与对照组比较,差异均无统计学意义。结论  沙利度胺联合CAG方案治疗老年AML患者能显著增加疗效,且安全性较好。
          关键词  沙利度胺;阿克拉霉素;粒细胞集落刺激因子;阿糖胞苷;急性髓系白血病;老年患者;Meta分析

          Meta-analysis  on  efficacy  and  safety  of  thalidomide  combined  with  CAG  regimen  in  the  treatment  of
          elderly patients with acute myeloid leukemia
          LI Xiaojing,HU Qi,LU Jiahui,LIU Min,DENG Jianqing,JIANG Wenwen,BAO Jizhang(Dept. of Hematology,
          Shanghai  Municipal  Hospital  of  Traditional  Chinese  Medicine,  Shanghai  University  of  Traditional  Chinese
          Medicine, Shanghai 200040, China)


          ABSTRACT   OBJECTIVE  To  systematically  evaluate  the  efficacy  and  safety  of  thalidomide  combined  with  aclacinomycin,
          granulocyte  colony-stimulating  factor  and  cytarabine (CAG)  regimen  in  the  treatment  of  elderly  patients  with  acute  myeloid
          leukemia (AML).  METHODS  CNKI,  Wanfang  data,  VIP,  Sino  Med,  PubMed,  Embase,  the  Cochrane  Library  and  Web  of
          Science  were  searched  comprehensively  from  the  inception  to  Aug.  27th,  2023.  Randomized  controlled  trials (RCTs)  about
          thalidomide  combined  with  CAG  regimen (trial  group)  versus  CAG  regimen (control  group)  in  the  treatment  of  elderly  AML
          patients were collected, and RevMan 5.3 software was used for meta-analysis of included studies. RESULTS Finally, 7 RCTs were
          included, with a total of 601 patients, including 307 patients in the trial group and 294 patients in the control group. Meta-analysis
          results showed that the trial group was superior to the control group in enhancing the overall response rate [Z=4.75, P<0.000 01,
          OR=2.80,  95%CI (1.83,4.28)],  complete  remission  rate  [Z=2.82,  P=0.005,  OR=1.61,  95%CI (1.16,  2.25)],  and  improving
                                                             platelet  count  [Z=2.70,  P=0.007,  MD=64.02,  95%CI
             Δ 基金项目 国家自然科学基金项目(No.81774258);上海市科技
                                                            (17.53,  110.51)],  vascular  endothelial  growth  factor  [Z=13.63,
          计划项目(No.23Y11921300,No.22Y11921100);上海市中医医院中医
          药传承人才培育项目(No.WLJH2021ZY-MZY033);上海市中医医院            P<0.000  01,  MD=-65.17,  95%CI(-74.54,  -55.80)],
          中医药科技发展项目(No.WL-XJRY-2021004K);中国民族医药学会科           vascular  endothelial  growth  factor  receptor  [Z=12.03,  P<
          研项目(No.2020ZY366-440401)                           0.000  01,  MD=-499.01,  95%CI ( -580.31,  -417.71)]
             *第一作者 住院医师,博士。研究方向:中西医结合防治血液病
                                                             and  basic  fibroblast  growth  factor  [Z=4.17,  P<0.000  1,
          的临床与基础。E-mail:2536414669@qq.com
             # 通信作者 副主任医师,副教授,硕士生导师,博士。研究方向:                 MD=-0.23,  95%CI(-0.35,  -0.12)].  And  there  was  no
          中西医结合防治血液病的临床与基础。E-mail:xyzsbjz@126.com            statistical  difference  between  the  trial  group  and  the  control


          中国药房  2024年第35卷第9期                                                China Pharmacy  2024 Vol. 35  No. 9    · 1139 ·
   116   117   118   119   120   121   122   123   124   125   126